China has historically been a small player in regard to patent filing. As recently as a decade ago,[i] China’s patent office, SIPO, which serves a country with three times the…
Tag: china
in Feature Post, IP Reform, Patent Practice, Patentability, Patents, Pharmaceutical Drugs0by Editor
680
China’s Bitter Medicine for Gilead: SIPO Cancels Viread Patent
Last August, China’s State Intellectual Property Office (SIPO) invalidated the core patent for Gilead Sciences‘ flagship drug Viread (as was reported by IPR Daily and a number of other news sources). This…
1st Guiding Case on Intellectual Property Now Available in English!
The re-posting of this blog is part of a cross-posting collaboration with the Stanford Law School China Guiding Cases Project. (more…)
Transplanting the Canadian UGC Exception to Hong Kong: Part 1
In July 2013, the Hong Kong government conducted a public consultation on the treatment of parody under the copyright regime. Building on two earlier consultations on digital copyright reform in…
Everything Old is New Again: Reframing the Cultural Explanation for Intellectual Property Infringement in China
Daniel Whalen won Canada’s IP Writing Challenge last year for his article, “Everything Old is New Again: Reframing the Cultural Explanation for Intellectual Property Infringement in China.” In anticipation for the…
Beer, Reform, and Policy: A Pint of Chinese Trade-mark Law
If you want to order a Heineken in China, just ask the bartender for a “喜力啤酒” (pronounced “see lee pee jow”). The second word-pair, “啤酒”(“pee jow”), simply means “beer” and…